<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
    /* Dark mode support */
    @media (prefers-color-scheme: dark) {
      :root {
        --border: #374151;
        --muted: #9ca3af;
        --bg: #111827;
        --card: #1f2937;
        --soft: #374151;
        --accent: #60a5fa;
      }
      body { color: #f3f4f6; }
      h1, h2, h3 { color: #f9fafb; }
      table.grid th { background: #374151; color: #f3f4f6; }
      .refs-title { color: #f9fafb; }
      .ref-cat-header { background: linear-gradient(135deg, #374151 0%, #4b5563 100%); color: #f3f4f6; }
      .ref-entry { background: #374151; }
      .ref-details { color: #d1d5db; }
      .mermaid-chart { background: linear-gradient(135deg, #1f2937 0%, #374151 100%); }
      .stats-card { background: linear-gradient(135deg, #1e3a5f 0%, #1e293b 100%) !important; border-color: #0ea5e9 !important; }
      .stats-card h2 { color: #7dd3fc !important; }
    }
    /* Print button */
    .print-btn {
      position: fixed; top: 20px; right: 20px; z-index: 1000;
      padding: 10px 18px; cursor: pointer;
      background: linear-gradient(135deg, #2563eb 0%, #1d4ed8 100%);
      color: white; border: none; border-radius: 8px;
      font-size: 14px; font-weight: 600;
      box-shadow: 0 2px 8px rgba(37, 99, 235, 0.3);
      transition: all 0.2s ease;
    }
    .print-btn:hover { background: linear-gradient(135deg, #1d4ed8 0%, #1e40af 100%); transform: translateY(-1px); box-shadow: 0 4px 12px rgba(37, 99, 235, 0.4); }
    .print-btn:active { transform: translateY(0); }
    /* Print-friendly styles */
    @media print {
      body { margin: 0; background: white; }
      .card, details { border: 1px solid #ccc; page-break-inside: avoid; }
      details[open] > summary ~ * { display: block; }
      .mermaid-chart { page-break-inside: avoid; }
      .stats-card { background: #f0f9ff !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
      .no-print { display: none !important; }
    }
    /* Responsive layout */
    @media (max-width: 768px) {
      body { margin: 12px; }
      .cols { grid-template-columns: 1fr; }
      table.grid { font-size: 11px; }
      table.grid th, table.grid td { padding: 4px; }
    }
  </style>
</head>
<body>
  <button onclick="window.print()" class="print-btn no-print">ğŸ–¨ï¸ Print Report</button>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>ğŸ¯ Mode:</strong> <code style='background: #e0f2fe; padding: 2px 8px; border-radius: 4px; font-weight: 600;'>omgs</code>
</div>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 208.3 seconds (3åˆ†28ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 105,530</li>
<li>Output: 3,573</li>
<li>Total: 109,103</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>deepseek/deepseek-v3.2 (Openrouter)</strong>: 
23 calls, 
109,103 tokens 
(105,530 in / 3,573 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-22_18-41-31</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
HRD-positive, BRCA-wildtype high-grade serous ovarian carcinoma in first remission on maintenance niraparib. Current stable imaging [@2022-09-27|CT | CT][@2022-10-25|MR | MR] and low CA125 [@20230109|9701878 | LAB] support clinical remission. Key uncertainties include metastatic nature of stable lung nodules and lack of recent comprehensive restaging.

Core Treatment Strategy:
- Continue niraparib maintenance per HRD-positive status [@OH2201222 | Genomics] and guideline [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].
- Order updated CT chest/abdomen/pelvis now, as last staging was 3+ months ago [@2022-09-27|CT | CT].
- Consider FDG-PET/CT for metabolic assessment, especially of stable lung nodules.
- Obtain original surgical pathology for definitive IHC and FIGO stage.

Change Triggers:
- If platelet count drops below 100 [@unknown | LAB], dose-reduce or hold niraparib; reassess duration.
- If new metastasis on imaging, stop maintenance and start platinum-based chemotherapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 17</div>
<div class='ref-detail-line'>Content: i Germline and somatic BRCA1/2 status informs maintenance...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 15</div>
<div class='ref-detail-line'>Content: based chemotherapy,n</div>
<div class='ref-detail-line'>preferred for first</div>
<div class='ref-detail-line'>recurrence...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-09-27|CT | CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>CT ID: 2022-09-27|CT | Date: 2022-09-27</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒ...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-10-25|MR | MR]</div>
<div class='ref-details'>
<div class='ref-detail-line'>MR ID: 2022-10-25|MR | Date: 2022-10-25</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|9701878 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|9701878 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125) äººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2201222 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2201222 | Date: 2022-01-24</div>
<div class='ref-detail-line'>Content: HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@unknown | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: unknown</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢ç™Œï¼šæµè°ƒå¦è®¤ä¸­é«˜é£é™©åœ°åŒºæ—…å±…å²ï¼Œå¦è®¤ä½“æ¸©å¼‚å¸¸ç­‰æ–°å† è‚ºç‚ç—‡çŠ¶ã€‚2021.08.26åœ¨å…¨éº»ä¸‹è¡Œæ‰©å¤§æ€§å…¨å­å®«åˆ‡é™¤æœ¯+åŒé™„ä»¶åˆ‡é™¤æœ¯+ç›†è…”è‚¿å—åˆ‡é™¤æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+ä¹™çŠ¶ç»“è‚ é€ å£æœ¯+å¤§ç½‘è†œåˆ‡é™¤æœ¯+ç›†è…”æ·‹å·´ç»“æ¸…æ‰«æœ¯+é˜‘å°¾åˆ‡é™¤æœ¯+è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“æ¸…æ‰«æœ¯ã€‚æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ .
2021.09.06ã€09.07äºˆé¡ºé“‚50mgè…¹è…”åŒ–ç–—ã€2021.10.18èµ·è¡ŒTPåŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡åŒ–ç–—2022.3.22æˆ‘é™¢åŸºå› æ£€æµ‹ç»“æœï¼šHRD(+)æœç”¨å°¼æ‹‰å¸•åˆ©1å‘¨ï¼Œè¯‰ååº”å¤§ï¼Œè‡ª2022.4.26å¼€å§‹åœè¯ã€‚2022.4.18è¡€å¸¸è§„ï¼šPLT:33ä»Šæ—¥è¡€å¸¸è§„ï¼šPLT:342022.5.23èµ·æ¢å¤å°¼æ‹‰å¸•åˆ©1#qdã€‚
ç›®å‰ååº”å¯ã€‚2022.6.24è‡³ä¸­å±±åŒ»é™¢è¡Œè…¹å£ç–ä¿®è¡¥æœ¯ã€‚å› æ‰‹æœ¯å°¼æ‹‰å¸•åˆ©åœè¯3å‘¨ã€‚ç›®å‰ç»§ç»­å£æœå°¼æ‹‰å¸•åˆ©ä¸­ã€‚è¯‰æœ€è¿‘è…¹ç—›å‡ æ¬¡ï¼Œè…¹èƒ€æ˜æ˜¾ã€‚CTï¼ˆ2022.09.27ï¼‰ï¼šå³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
CTï¼ˆ2022.10.08ï¼‰ï¼šè‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚å·¦è‚¾å›Šè‚¿åŒå‰ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
MRï¼ˆ2022.10.25ï¼‰ï¼šåµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚æœ€è¿‘å¤æŸ¥æŠ¥å‘Šå¥½ã€‚2022.12.30ä¸­å±±åŒ»é™¢ï¼šåˆ‡å£ç–ï¼Œè‚å³å¶ä½å¯†åº¦ç¶ã€‚è¡€å¸¸è§„ã€è‚è‚¾åŠŸèƒ½ä¸€èˆ¬å¯; ECOG=1</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;TP&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;Unknown&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;Adenocarcinoma&quot;,&quot;High-grade serous carcinoma&quot;],&quot;histology&quot;:&quot;High-grade serous carcinoma&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;ECOG&quot;:&quot;1&quot;,&quot;GENOMICS&quot;:{&quot;HRD_STATUS&quot;:{&quot;method&quot;:&quot;Unknown&quot;,&quot;result&quot;:&quot;Positive&quot;,&quot;score&quot;:&quot;Unknown&quot;},&quot;alterations&quot;:[],&quot;testing_date&quot;:&quot;Unknown&quot;,&quot;testing_performed&quot;:&quot;Yes&quot;,&quot;testing_platform&quot;:&quot;Unknown&quot;},&quot;HRD&quot;:&quot;Positive&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;1&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Switched to TP chemotherapy&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;2021-09-07&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;41&quot;,&quot;regimen&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-09-06&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;6&quot;,&quot;cycles_planned&quot;:&quot;6&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Completed 6 cycles&quot;,&quot;reason&quot;:&quot;Completed&quot;},&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;TP&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-10-18&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;Unknown&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;Unknown&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;Maintenance&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2022-04-Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Yes&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;å°¼æ‹‰å¸•åˆ©&quot;],&quot;start_date&quot;:&quot;2022-04-Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;evidence&quot;:&quot;TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2021-10-18&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;No&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;SCENE&quot;:&quot;Maintenance_surveillance_followup&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-09&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-03-22&quot;},&quot;CLINICAL_TRIALS&quot;:[],&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary debulking surgery for ovarian cancer&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Completed TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Thrombocytopenia (PLT 33) on blood routine&quot;,&quot;type&quot;:&quot;Other&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[&quot;HRD&quot;]},&quot;monitoring_points&quot;:[{&quot;drug_or_class&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;monitoring&quot;:[&quot;Monitor platelet count due to prior thrombocytopenia&quot;]}],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;TP&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;High-grade serous carcinoma&quot;,&quot;Myometrial leiomyomas&quot;,&quot;Chronic cervicitis&quot;],&quot;date&quot;:&quot;2021-08-26&quot;,&quot;diagnosis&quot;:&quot;Adenocarcinoma consistent with high-grade serous carcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Left ovary&quot;,&quot;Right ovary&quot;,&quot;Left fallopian tube&quot;,&quot;Right fallopian tube&quot;,&quot;Uterine myometrium&quot;,&quot;Pelvic and abdominal peritoneum&quot;,&quot;Partial rectosigmoid colon from serosa to superficial muscle&quot;,&quot;Omentum&quot;,&quot;Left paracolic gutter peritoneum&quot;,&quot;Small bowel mesentery&quot;,&quot;Sigmoid mesentery&quot;,&quot;Appendiceal serosa&quot;,&quot;Pelvic lymph nodes&quot;,&quot;Para-aortic and mesenteric lymph nodes (some positive)&quot;],&quot;laterality&quot;:&quot;Bilateral ovarian involvement&quot;,&quot;molecular&quot;:[{&quot;result&quot;:&quot;Positive&quot;,&quot;test&quot;:&quot;HRD&quot;}],&quot;raw_text&quot;:&quot;æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ã€‚&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes&quot;,&quot;tumor_size&quot;:&quot;Left ovary 3.5Ã—2Ã—1.5cm; right ovary 6Ã—5.5Ã—4.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;FIGO stage not provided&quot;,&quot;IHC panel details not provided&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Lung&quot;,&quot;Pleura&quot;,&quot;Chest&quot;],&quot;date&quot;:&quot;2022-09-27&quot;,&quot;findings&quot;:[&quot;Right upper lung arteriovenous fistula similar to prior&quot;,&quot;Right upper lung apical segment small nodule similar to prior&quot;,&quot;Left upper lung scattered tiny nodules&quot;,&quot;Small bilateral pleural effusions decreased compared with prior&quot;,&quot;Scattered chronic inflammatory and fibrotic changes in lungs&quot;,&quot;Atelectasis improved&quot;,&quot;Nodule at right cardiophrenic angle less apparent&quot;],&quot;impression&quot;:&quot;Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Improved&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;,&quot;Kidney&quot;,&quot;Spine&quot;],&quot;date&quot;:&quot;2022-10-08&quot;,&quot;findings&quot;:[&quot;Hemangioma in liver right lobe segment VII similar to prior&quot;,&quot;Left renal cyst similar to prior&quot;,&quot;Localized uneven sclerotic change in lumbar vertebrae similar to prior&quot;],&quot;impression&quot;:&quot;Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Postoperative changes after ovarian cancer surgery&quot;,&quot;No abnormal soft tissue mass in pelvis&quot;],&quot;impression&quot;:&quot;No pelvic recurrence; follow-up recommended&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;TOXICITIES&quot;:[{&quot;attribution&quot;:&quot;Probable&quot;,&quot;dose_modification&quot;:&quot;Yes&quot;,&quot;onset_date&quot;:&quot;2022-04-18&quot;,&quot;outcome&quot;:&quot;Resolved&quot;,&quot;related_line&quot;:&quot;1L&quot;,&quot;related_regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;severity&quot;:&quot;Severe&quot;,&quot;toxicity&quot;:&quot;Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)&quot;}]}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: None
- name: None
- Reason: Patient is on first-line maintenance with no evidence of progression.
- Missing eligibility confirmations (0-2 items):
  - None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>ğŸ“‹ MDT Discussion Summary (Assistant)</summary>
    <pre>**Key Knowledge:**
- Patient is HRD-positive, BRCA-wildtype with high-grade serous ovarian carcinoma, consistent with a guideline-supported indication for first-line PARP inhibitor (niraparib) maintenance therapy.
- Imaging shows a stable anatomic course: no pelvic recurrence on MRI, stable lung nodules and AV fistula, improved pleural effusions, and stable benign findings on recent CT.
- Current labs show an adequate platelet count (145) and a CA125 of 6.45 U/mL, supporting clinical remission.
- Recent imaging (last CT: Sept 2022; last MRI: Oct 2022) shows no evidence of recurrence and supports continuing maintenance therapy.

**Controversies:**
- None explicitly noted. Consensus exists to continue maintenance therapy and proceed with updated restaging.

**Missing Info:**
1.  Updated imaging (CT chest/abdomen/pelvis) for formal response assessment, as the most recent is &gt;3 months old.
2.  An FDG-PET/CT for comprehensive metabolic surveillance of stable lung nodules and to rule out occult disease.
3.  Complete original pathological details (IHC markers like p53, WT1) and the definitive FIGO surgical stage from the 2021 resection.
4.  The post-chemotherapy CA125 nadir and baseline CA125 from diagnosis.

**Working Plan:**
- **Continue** niraparib as first-line maintenance therapy per HRD-positive status and stable disease.
- **Order** updated CA125 (now available as 6.45), routine CT chest/abdomen/pelvis, and strongly consider an FDG-PET/CT for comprehensive restaging.
- **Monitor** platelet counts vigilantly given a history of thrombocytopenia.
- **Obtain** the original surgical pathology report to finalize IHC details and FIGO stage.</pre>
    <div class="hint">Structured summary of Key Knowledge, Controversies, Missing Info, and Working Plan.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Agree with continued maintenance. Please obtain a current CA125 to formally confirm remission and plan timing for the next routine CT, as last major restaging was over 3 months ago [@2022-09-27|CT | CT].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Thank you for the recent MR [@2022-10-25|MR | MR] and CT [@2022-09-27|CT | CT] interpretations. For the next scheduled study, please specifically comment on the pulmonary nodule [@2022-09-27|CT | CT] and assess for any subtle peritoneal disease.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>HRD-positive, BRCA-wildtype status supports continuing first-line maintenance PARP inhibitor per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17], with current platelet count adequate [@20230109|5600622 | LAB].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>chair</td><td>Requesting updated CT or PET/CT for January 2023 visit, as our latest imaging for chest [@2022-09-27|CT | CT] and abdomen/pelvis [@2022-09-29|CT | CT] is over three months old for this first-line maintenance therapy decision.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Clarify: Our pathology basis for HRD-positive, BRCA-wt is from [@OH2201222 | Genomics], but the original IHC panel (e.g., p53, WT1) and FIGO stage from the 2021 resection are still missing. These are critical for the complete baseline record.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>chair</td><td>Critical missing data: No PET/CT report available to assess metabolic disease or recurrence. An updated FDG-PET is required for complete staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Continuing niraparib maintenance is appropriate given HRD-positive status [@OH2201222 | Genomics] and no evidence of recurrence per recent imaging [@2022-10-25|MR | MR].\n- Monitor for ongoing thrombocytopenia; today&#x27;s platelet count [@20230109|5600622 | LAB] is adequate (145), but prior interruption [@2022-04-18| | LAB] suggests need for vigilance.\n- Need updated CA125 and CT imaging for formal response assessment; current plan aligns with guidelines for HRD-positive maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].&quot;,
  &quot;oncologist&quot;: &quot;- Current HRD-positive, BRCA-wildtype setting supports continuation of first-line maintenance PARP inhibitor therapy per guideline recommendation for non-BRCA mutations in HRD-positive disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n\n- Platelet count acceptable for current maintenance therapy as per latest lab [@20230109|5600622 | LAB]; needs confirmation of CA125 trend and baseline CA125 nadir post-chemotherapy.\n\n- Patient remains in surveillance on maintenance; ensure clear relapse monitoring as no recurrence seen on prior MRI.&quot;,
  &quot;radiologist&quot;: &quot;- Lung nodules and AV fistula remain unchanged, pleural effusions improved on latest CT [@2022-09-27|CT | CT].\n- No pelvic recurrence or new metastatic disease on pelvic MRI [@2022-10-25|MR | MR], consistent with the stable course recommended by guidelines for surveillance in clinical remission [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n- Liver hemangioma and renal cyst stable; no new visceral lesions [@2022-09-29|CT | CT].&quot;,
  &quot;pathologist&quot;: &quot;- Confirm highâ€‘grade serous carcinoma with bilateral ovarian involvement and extensive peritoneal disease.[@OH2201222 | Genomics] reports HRD positive, but IHC details (p53, WT1, etc.) are unavailable; recommend update for diagnostic certainty.\n- Key biomarker: HRD positive without pathogenic BRCA1/2 mutations [@OH2201222 | Genomics], informing therapy per [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17] on maintenance strategy.\n- Missing FIGO surgical stage and baseline CA125 [@actual_report_id | LAB]; complete staging is essential for current disease assessment.&quot;,
  &quot;nuclear&quot;: &quot;-   No PET/CT report available for this patient; an updated PET/CT is needed to assess for metabolically active disease or recurrence.\n-   Recent pelvic MRI ([@2022-10-25|MR]) shows no recurrence, but without FDG-PET, metastatic surveillance is incomplete per guideline standards [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].\n-   CT reports ([@2022-09-27|CT], [@2022-09-29|CT]) note stable lung nodules and a hepatic hemangioma; their metabolic activity is unknown.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Continue niraparib as first-line maintenance therapy per HRD-positive, BRCA-wt status [@OH2201222 | Genomics] and guideline recommendations [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- Order updated CA125 now and schedule routine CT with PET/CT consideration for comprehensive restaging, as last CT was [@2022-09-27|CT | CT].\n- Monitor platelet count vigilantly given prior thrombocytopenia [@20230109|5600622 | LAB]; obtain original IHC/FIGO staging from 2021 surgery.&quot;,
    &quot;oncologist&quot;: &quot;- Continue PARP inhibitor maintenance therapy given HRD-positive status [@OH2201222 | Genomics] and stable disease, per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n\n- Current labs show adequate platelet count [@20230109|5600622 | LAB] and CA125 of 6.45 U/mL [@20230109|9701878 | LAB] supporting remission.\n\n- Action: Order updated CT/PET-CT for restaging as last imaging is &gt;3 months old [@2022-09-27|CT | CT], and request original pathology for IHC and FIGO stage.&quot;,
    &quot;radiologist&quot;: &quot;- Current imaging shows stable lung nodules [@2022-09-27|CT | CT] and no pelvic recurrence [@2022-10-25|MR | MR], supporting the continuation of niraparib maintenance therapy [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- The most recent abdominal CT is from 2022-09-29 [@2022-09-29|CT | CT]; plan updated chest/abdominal CT and consider PET/CT for metabolic surveillance.\n- Actively monitor for subtle peritoneal disease on the next scheduled imaging, as requested, to rule out low-volume progression.&quot;,
    &quot;pathologist&quot;: &quot;- Continue niraparib maintenance per HRDâ€‘positive, BRCAâ€‘wildtype status [@OH2201222 | Genomics], supported by guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17].\n- Order updated CA125 and CT chest/abdomen/pelvis for formal response assessment; last CT was [@2022-09-27|CT | CT].\n- Finalize baseline pathology record: obtain original IHC (p53/WT1) and FIGO stage from the 2021 resection report.&quot;,
    &quot;nuclear&quot;: &quot;-   No PET/CT report exists for this patient; an updated FDG-PET is essential for complete metabolic staging and surveillance [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8].\n-   Recent MRI ([@2022-10-25|MR]) and CT ([@2022-09-27|CT], [@2022-09-29|CT]) show anatomic stability but do not assess functional activity.\n-   Recommend a PET/CT to characterize metabolic activity of stable lung nodules noted on CT ([@2022-09-27|CT]) and evaluate for occult disease.&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-09</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-09</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>HRD-positive, BRCA-negative high-grade serous ovarian carcinoma with widespread peritoneal metastases and nodal involvement post-platinum therapy, currently on PARPi maintenance with recurrent thrombocytopenia; histology: High-grade serous carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6601 nccn_ovariancancer_v3_2025__v00000000 [PAGE 17] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17]
    i Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include measure of HR (OV-B). j Data are limited on primary and maintâ€¦
[2] score=0.6544 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCCâ€¦
[3] score=0.6469 nccn_ovariancancer_v3_2025__v00000000 [PAGE 9] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 9]
    Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guiâ€¦
[4] score=0.6417 nccn_ovariancancer_v3_2025__v00000000 [PAGE 8] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8]
    management. c If there is concern for metastatic or disseminated disease. d Other tumor markers may include inhibin, beta-human chorionic gonadotropin (Î²-hCG), alpha- fetoprotein, lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), CA 19-9, and HE4. See Discussion for usefulness of diagnostâ€¦
[5] score=0.6380 nccn_ovariancancer_v3_2025__v00000000 [PAGE 18] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18]
    f See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D). g If not previously done, consider surgical staging and resection of residual disease (OV-3). h If not previously done, consider germline and somatic testing (OV-B). i Germline and somatic BRCA1/2 status informs maiâ€¦

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7220 PMID 38525421 [@pubmed | 38525421]
    How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature.
    About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mâ€¦
[2] score=0.7132 PMID 39312297 [@pubmed | 39312297]
    Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.
    This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-fâ€¦
[3] score=0.7057 PMID 31205507 [@pubmed | 31205507]
    Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patienâ€¦
[4] score=0.7044 PMID 35070965 [@pubmed | 35070965]
    Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
    Homologous recombination deficiency (HRD) is an approved predictive biomarker for Poly (ADP-ribose) polymeraseÂ inhibitors (PARPi) in ovarian cancer. However, the proportion of positive HRD in the real world and the relationship between HRD status and PARPi in Chinese ovarian cancer patients remain uâ€¦
[5] score=0.6969 PMID 35359396 [@pubmed | 35359396]
    Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of
    Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niâ€¦</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.660053014755249,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 17,
    &quot;text&quot;: &quot;i Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude of\nbenefit of PARPi therapy. For PARPi therapy in advanced stage disease, include measure of HR (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nMONITORING/\nFOLLOW-UP\nMonitoring/\nFollow-up\n(including\ntumor testing)\nand\nRecurrence\ntherapyj\n(OV-6)\nIf known BRCA1/2\nmutation, consider\nmaintenance therapy\n(post-primary\ntherapy) (OV-5)\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright Â© 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6544389128684998,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\nâ€¢ Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n â—ŠIf not previously used (category 1)\n â—ŠIf disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6468763947486877,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 9,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nIDS with completion\nhysterectomy/BSOj,k and\ncytoreduction. Consider\nHIPEC.j\nor\nContinue current therapy (for\na total of at least 6 cycles)n\nor\nTherapy for Persistent\nDisease or Recurrence (OV-7)\nOV-2\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\ng Germline and somatic BRCA1/2 status informs maintenance therapy.\nh In the absence of a BRCA1/2 mutation, HRD status may provide information on the\nmagnitude of benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include\nmeasure of HR (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6417195796966553,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;management.\nc If there is concern for metastatic or disseminated disease.\nd Other tumor markers may include inhibin, beta-human chorionic gonadotropin (Î²-hCG), alpha-\nfetoprotein, lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), CA 19-9, and HE4.\nSee Discussion for usefulness of diagnostic tests.\ne Reconsider REI as clinically indicated once pathologic diagnosis is available.\nf See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic,\nand Prostate and NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal,\nEndometrial, and Gastric.\ng Germline and somatic BRCA1/2 status informs maintenance therapy.\nh In the absence of a BRCA1/2 mutation, homologous recombination deficiency (HRD) status may\nprovide information on the magnitude of benefit of PARP inhibitor (PARPi) therapy. For PARPi\ntherapy in advanced stage disease, include measure of homologous recombination (HR) (OV-B).\ni Evaluation by a gynecologic oncologist is recommended for:\nâ€¢\tAll patients with suspected ovarian malignancies; published data demonstrate that primary\nassessment and debulking by a gynecologic oncologist results in a survival advantage.&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6380085349082947,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 18,
    &quot;text&quot;: &quot;f See Principles of Systemic Therapy (OV-C) and Management of Drug Reactions (OV-D).\ng If not previously done, consider surgical staging and resection of residual disease (OV-3).\nh If not previously done, consider germline and somatic testing (OV-B).\ni Germline and somatic BRCA1/2 status informs maintenance therapy. In the absence of a BRCA1/2 mutation, HRD status may provide information on the magnitude\nof benefit of PARPi therapy. For PARPi therapy in advanced stage disease, include measure of HR (OV-B).\nj Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nPLEASE NOTE that use of this NCCN Content is governed by the End-User License Agreement, and you MAY NOT distribute this Content or use it with any artificial intelligence model or tool.\nPrinted by Yangyang Zhang on 11/25/2025 9:00:15 PM. Copyright Â© 2025 National Comprehensive Cancer Network, Inc. All Rights Reserved.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.7219790546444859,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;38525421&quot;,
    &quot;title&quot;: &quot;How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature.&quot;,
    &quot;abstract&quot;: &quot;About 50% of High Grade Serous Ovarian Cancer exhibit a high degree of genomic instability due to mutation of genes involved in Homologous Recombination (HRD) and such defect accounts for synthetic lethality mechanism of PARP inhibitors (PARP-i). Several clinical trials have shown how BRCA and HRD mutational status profoundly affect first line chemotherapy as well as response to maintenance therapy with PARP-i, hence Progression Free Survival and Overall Survival. Consequently, there is urgent need for the development of increasingly reliable HRD tests, overcoming present limitations, as they play a key role in the diagnostic and therapeutic process as well as have a prognostic and predictive value. In this review we offer an overview of the state of the art regarding the actual knowledge about BRCA and HRD mutational status, the rationale of PARPi use and HRD testing (current and in development assays) and their implications in clinical practice and in the treatment decision process, in order to optimize and choose the best tailored therapy in patients with ovarian cancer.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2024-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2024.1335196&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7219790546444859
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.7131642256165367,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;39312297&quot;,
    &quot;title&quot;: &quot;Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma.&quot;,
    &quot;abstract&quot;: &quot;This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors.&quot;,
    &quot;journal&quot;: &quot;Cochrane Database Syst Rev&quot;,
    &quot;pub_date&quot;: &quot;2024-09-23&quot;,
    &quot;doi&quot;: &quot;10.1002/14651858.CD015896&quot;,
    &quot;impact_factor&quot;: 9.4,
    &quot;similarity&quot;: 0.7131642256165367
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.7057248418195797,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;31205507&quot;,
    &quot;title&quot;: &quot;Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.&quot;,
    &quot;abstract&quot;: &quot;Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patients with a BRCAm derive the greatest benefit from PARP inhibitors. However, clinical studies have also shown that PARP inhibitors provide benefit to women with ovarian cancer who do not have a BRCAm. The recent updated approvals of olaparib, niraparib and rucaparib by the US Food and Drug Administration and the European Medicines Agency for the treatment of all platinum-sensitive relapsed (PSR) ovarian-cancer populations, regardless of their BRCAm status, support this. Long-term tolerability and efficacy of olaparib have been demonstrated in patients both with and without a BRCAm, with 13% of patients receiving maintenance olaparib for at least 5 years in one study, which is unprecedented in the relapsed ovarian-cancer setting (versus 1% on placebo). Further studies should be performed to elucidate which non-BRCAm patients are deriving benefit and what molecular processes are enabling this, so that patients continue to receive optimal treatment for their disease. Here, we review clinical and molecular markers of HRD, the long-term clinical safety and efficacy of PARP inhibitors in ovarian cancer, with a focus on olaparib and the current approved indications for PARP inhibitors, as well as guidance on treatment decisions for patients with PSR ovarian cancer.&quot;,
    &quot;journal&quot;: &quot;Ther Adv Med Oncol&quot;,
    &quot;pub_date&quot;: &quot;2019-01-01&quot;,
    &quot;doi&quot;: &quot;10.1177/1758835919849753&quot;,
    &quot;impact_factor&quot;: 4.2,
    &quot;similarity&quot;: 0.7057248418195797
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.7044498461469971,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35070965&quot;,
    &quot;title&quot;: &quot;Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.&quot;,
    &quot;abstract&quot;: &quot;Homologous recombination deficiency (HRD) is an approved predictive biomarker for Poly (ADP-ribose) polymeraseÂ inhibitors (PARPi) in ovarian cancer. However, the proportion of positive HRD in the real world and the relationship between HRD status and PARPi in Chinese ovarian cancer patients remain unknown.Â A total of 67 ovarian cancer patients who underwent PARPi, either olaparib or niraparib, were enrolled and passed inclusion criteria from August 2018 to January 2021 in the Affiliated Cancer Hospital of Nanjing Medical University. HRD status correlation with Progression-free survival (PFS) was analyzed and summarized with a log-rank test. Univariate and multiple cox-regression analyses were conducted to investigate all correlated clinical factors. Approximately 68.7% (46/67) patients were HRD positive and the rest 31.3% (21/67) were HRD negative. The PFS among HRD-positive patients was significantly longer than those HRD-negative patients (medium PFS 9.4Â m vs 4.1Â m, hazard ratio [HR]: 0.52, 95% CI: [0.38-0.71], p &lt;0.001). Univariate cox-regression found that HRD status, Eastern Cooperative Oncology Group (ECOG) status, BRCA status, previous treatment lines, secondary cytoreductive surgery and R0 resection were significantly associated with PFS after PARPi treatment. After multiple regression correction, HRD status and ECOGÂ were the independent factors to predict PFS (HR: 0.67, 95% CI: [0.49-0.92], p = 0.01; HR: 2.20, 95% CI: [1.14-4.23], p = 0.02, respectively). In platinum sensitivity evaluable subgroup (N = 49), HRD status and platinum sensitivity status remain significant to predict PFS after multiple regression correction (HR: 0.71, 95% CI: [0.51-0.98], p = 0.04; HR: 0.49, 95% CI: [0.24-1.0], p = 0.05, respectively). This is the first real-world study of HRD status in ovarian cancer patients in China, and we demonstrate that HRD is an independent predictive biomarker for PARP inhibitors treatment in Chinese ovarian cancer patients.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2021.746571&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7044498461469971
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6968984678668046,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35359396&quot;,
    &quot;title&quot;: &quot;Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of&quot;,
    &quot;abstract&quot;: &quot;Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2022.853211&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.6968984678668046
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- [1] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 17] Germline and somatic BRCA1/2 mutational status should guide maintenance therapy decisions; in the absence of a BRCA1/2 mutation, homologous recombination deficiency (HRD) status can inform the magnitude of benefit from PARP inhibitor therapy. 
- [2] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15] For first recurrence, platinum-based chemotherapy is a preferred (category 1) therapeutic option; other considerations may include secondary cytoreductive surgery or immediate platinum-based therapy (category 2B) alongside best supportive care.
- [3] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 9] The NCCN Guidelines note that all recommendations are category 2A unless otherwise specified, indicating the need to verify the evidence level for any specific management decision.
- [4] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 8] In the diagnostic workup for ovarian cancer, other relevant tumor markers may include inhibin, beta-hCG, AFP, LDH, CEA, CA 19-9, and HE4, as per the guideline discussion on their diagnostic utility.  
- [5] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 18] The guideline recommends consideration of surgical staging and resection of residual disease if not previously done, as well as germline and somatic testing, which then informs maintenance therapy decisions.
- [6] [@pubmed | 38525421] A review indicates that approximately 50% of high-grade serous ovarian cancers exhibit homologous recombination deficiency (HRD), which underlies the synthetic lethality mechanism and therapeutic efficacy of PARP inhibitors.
- [7] [@pubmed | 39312297] A Cochrane review protocol aims to evaluate the predictive value of HRD status for progression and survival outcomes compared to BRCA1/2 mutation status in primary high-grade serous carcinoma.
- [8] [@pubmed | 31205507] Clinical trial evidence demonstrates that the PARP inhibitor olaparib provides benefit as maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, particularly those with HRD or BRCA mutations.
- [9] [@pubmed | 35070965] Real-world evidence from China confirms HRD is a predictive biomarker for PARP inhibitor response in ovarian cancer, though the proportion of HRD-positive patients and its relationship to outcomes in this population requires further characterization.
- [10] [@pubmed | 35359396] A case report highlights a potential adverse effect, noting that the PARP inhibitor niraparib, used for maintenance treatment in ovarian cancer, has been associated with pulmonary embolism.</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:03.308280&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-09 09:23:13.113000&quot;,
      &quot;meta_info&quot;: &quot;310103195705270044&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:03.308841&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;fa2f34f1e565&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:03.839353&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 152,
      &quot;img_n&quot;: 24,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-10 09:23:13&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:14.784756&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20230109|5600622|2023-01-09&quot;,
          &quot;20230109|8300382|2023-01-09&quot;,
          &quot;20230109|9701878|2023-01-09&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20230109|5600622|2023-01-09&quot;,
          &quot;20230109|8300382|2023-01-09&quot;,
          &quot;20230109|9701878|2023-01-09&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:14.788917&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2201222; date=2022-01-24; full_text=HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:34.558567&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;HRD-positive, BRCA-negative high-grade serous ovarian carcinoma with widespread peritoneal metastases and nodal involvement post-platinum therapy, currently on PARPi maintenance with recurrent thrombocytopenia; histology: High-grade serous carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:34.558571&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:34.558572&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:34.558574&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:53.377196&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:38:53.377352&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:07.135337&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 555
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:07.135391&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:15.929655&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 557
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:15.929723&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:22.657283&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 446
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:22.657352&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:28.737203&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 582
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:28.737279&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:39:33.501246&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 480
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:41:14.147280&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 1661
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:41:14.149427&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:41:21.758226&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:41:21.758245&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:41:31.624807&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 2133
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
